Andrew Fein

Biogen Inc (NASDAQ:BIIB) reported better-than-expected fourth-quarter results, prompting analysts to share insights on the company’s trajectory. Wedbush analyst Laura Chico maintained a Neutral rating, while lifting the price target from $178 to $187. HC Wainwright analyst Andrew Fein...

Positive results from primary clinical data regarding UBX1325 have H.C. Wainwright & Co. analysts bullish UNITY Biotechnology, Inc. (NASDAQ: UBX). The Unity Biotech Analyst: Andrew Fein reaffirmed a Buy rating on shares of Unity Biotech with a $12 price target. The Unity Biotech...

Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over 38%.  The Biogen Analysts: Morgan Stanley analyst Matthew Harrison maintained an Overweight rating on Biogen shares and increased the price target from...

Amarin Corporation plc (NASDAQ: AMRN) shares were tumbling Tuesday in reaction to a negative verdict issued by a U.S. District Court regarding generic versions of its fish oil pill Vascepa. Amarin shares, which rose to 52-week high of $26.12 in mid-December in reaction to a Vascepa...

Christmas came early for Amarin Corporation plc (NASDAQ: AMRN) with the FDA's approval of an expanded label for its fish oil pill Vascepa ahead of a scheduled Dec. 28 decision date.  The label expansion approved Friday includes the indication of cardiovascular risk reduction in...

Following Biogen Inc's (NASDAQ: BIIB) presentation of detailed top-line results for aducanumab at the Alzheimer's conference, the stock ended Thursday's session up about 3.5%. The presentation polarized analysts and clinicians alike, stirring a debate on whether the data is sufficient...

Aimmune Therapeutics Inc (NASDAQ: AIMT)'s peanut allergy product candidate Palforzia to treat peanut allergy in children and adolescents has received the backing of an FDA panel that reviewed the NDA. Following the positive verdict, H.C. Wainwright looked at what the decision means...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares, which rallied over 63% Monday following positive results from its pimavanserin in dementia-related psychosis, were seeing further upward momentum Tuesday.  The Analysts H.C. Wainwright & Co. analyst Andrew Fein reiterated a Buy...

Biogen Inc (NASDAQ: BIIB) announced Monday a deal to buy gene therapy biotech Nightstar Therapeutics PLC (NASDAQ: NITE) for $800 million. The Analysts Baird analyst Brian Skorney maintained a Neutral rating on Biogen with a $348 price target. H.C. Wainwright analyst Andrew Fein reiterated a Buy...

NeuroMetrix Inc (NASDAQ: NURO) is a commercial-stage health care technology company with two products on the market: Quell, an OTC wearable device relying on neurostimulation technology for chronic pain relief; and DPNCheck, a point-of-care diabetic peripheral neuropathy test. With $...

Insmed Incorporated (NASDAQ: INSM) stock crashed Monday after the U.S. Food & Drug Administration approved the company’s antibiotic Arikayce. In addition to “sell the news” traders moving on following the FDA approval, some sellers are likely concerned about the revelation...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on Tuesday reported second-quarter earnings, which consisted of a better than expected loss per share (53 cents versus expectations for 62 cents)and a revenue beat ($35.6 million versus expectations for $32.03 million). Sales of the company's only...

Following the failure of Axovant Sciences Ltd (NASDAQ: AXON)'s late-stage MINDSET study, which evaluated its Alzheimer's treatment candidate intepirdine, Baird said its bull thesis is blown out. However, HC Wainwright said the setback is not the end of the world for the company. Baird...

Shares of Concert Pharmaceuticals Inc (NASDAQ: CNCE) gained more than 13 percent Monday morning and traded above the $15 per share for the first time since early May after analysts at H.C. Wainwright & Co. initiated coverage of the stock with a bullish rating. Wainwright's Andrew Fein initiated...

Axovant Sciences Ltd (NYSE: AXON) reported its fiscal fourth-quarter results on Tuesday, which helped push shares higher by more than 3.5 percent on Wednesday. Investors could potentially be rewarded with another upcoming catalyst in September with topline Phase 3 MINDSET results, analysts at HC...